AR121118A1 - Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau - Google Patents
Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tauInfo
- Publication number
- AR121118A1 AR121118A1 ARP210100163A ARP210100163A AR121118A1 AR 121118 A1 AR121118 A1 AR 121118A1 AR P210100163 A ARP210100163 A AR P210100163A AR P210100163 A ARP210100163 A AR P210100163A AR 121118 A1 AR121118 A1 AR 121118A1
- Authority
- AR
- Argentina
- Prior art keywords
- zinc finger
- repress
- transcription factors
- finger protein
- tau expression
- Prior art date
Links
- 102000038627 Zinc finger transcription factors Human genes 0.000 title 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Immunology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964501P | 2020-01-22 | 2020-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121118A1 true AR121118A1 (es) | 2022-04-20 |
Family
ID=74661487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100163A AR121118A1 (es) | 2020-01-22 | 2021-01-22 | Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230242602A1 (https=) |
| EP (1) | EP4093754A1 (https=) |
| JP (1) | JP2023511908A (https=) |
| KR (1) | KR20220131273A (https=) |
| CN (1) | CN115210251A (https=) |
| AR (1) | AR121118A1 (https=) |
| AU (1) | AU2021209699A1 (https=) |
| BR (1) | BR112022014160A2 (https=) |
| CA (1) | CA3168805A1 (https=) |
| IL (1) | IL294535A (https=) |
| MX (1) | MX2022008953A (https=) |
| TW (1) | TW202134288A (https=) |
| UY (1) | UY39036A (https=) |
| WO (1) | WO2021151012A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL266862B2 (en) | 2016-12-01 | 2024-01-01 | Sangamo Therapeutics Inc | Tau modulators and methods and preparations for their administration |
| WO2020072677A1 (en) | 2018-10-02 | 2020-04-09 | Sangamo Therapeutics, Inc. | Methods and compositions for modulation of tau proteins |
| AU2020356962A1 (en) * | 2019-10-02 | 2022-04-14 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for repressing alpha-synuclein expression |
| WO2025193848A1 (en) * | 2024-03-13 | 2025-09-18 | Sangamo Therapeutics, Inc. | Delivery of tau repressors using the blood-brain barrier penetrant capsid |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69534629D1 (de) | 1994-01-18 | 2005-12-29 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| USRE39229E1 (en) | 1994-08-20 | 2006-08-08 | Gendaq Limited | Binding proteins for recognition of DNA |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| ES2341926T3 (es) | 1998-03-02 | 2010-06-29 | Massachusetts Institute Of Technology | Poliproteinas con dedos de cinc que tienen enlazadores mejorados. |
| ATE355368T1 (de) | 2000-01-24 | 2006-03-15 | Gendaq Ltd | Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| US9394531B2 (en) | 2008-05-28 | 2016-07-19 | Sangamo Biosciences, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
| HRP20200254T1 (hr) | 2010-05-03 | 2020-05-29 | Sangamo Therapeutics, Inc. | Pripravci za povezivanje modula cink fingera |
| CA3131284C (en) | 2013-08-28 | 2023-09-19 | David Paschon | Compositions for linking dna-binding domains and cleavage domains |
| CN106459894B (zh) | 2014-03-18 | 2020-02-18 | 桑格摩生物科学股份有限公司 | 用于调控锌指蛋白表达的方法和组合物 |
| WO2017011556A1 (en) * | 2015-07-13 | 2017-01-19 | The General Hospital Corporation | Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof |
| KR20180101442A (ko) | 2016-02-02 | 2018-09-12 | 상가모 테라퓨틱스, 인코포레이티드 | Dna-결합 도메인 및 절단 도메인을 연결시키기 위한 조성물 |
| KR102455249B1 (ko) | 2016-08-24 | 2022-10-17 | 상가모 테라퓨틱스, 인코포레이티드 | 가공된 표적 특이적 뉴클레아제 |
| IL266862B2 (en) * | 2016-12-01 | 2024-01-01 | Sangamo Therapeutics Inc | Tau modulators and methods and preparations for their administration |
| WO2020072677A1 (en) | 2018-10-02 | 2020-04-09 | Sangamo Therapeutics, Inc. | Methods and compositions for modulation of tau proteins |
| EP3861130A4 (en) | 2018-10-02 | 2022-08-03 | Sangamo Therapeutics, Inc. | GENETIC MODULATORS |
-
2021
- 2021-01-22 TW TW110102602A patent/TW202134288A/zh unknown
- 2021-01-22 IL IL294535A patent/IL294535A/en unknown
- 2021-01-22 UY UY0001039036A patent/UY39036A/es not_active Application Discontinuation
- 2021-01-22 BR BR112022014160A patent/BR112022014160A2/pt not_active Application Discontinuation
- 2021-01-22 CN CN202180010601.9A patent/CN115210251A/zh active Pending
- 2021-01-22 WO PCT/US2021/014780 patent/WO2021151012A1/en not_active Ceased
- 2021-01-22 AU AU2021209699A patent/AU2021209699A1/en active Pending
- 2021-01-22 KR KR1020227028167A patent/KR20220131273A/ko active Pending
- 2021-01-22 EP EP21706102.7A patent/EP4093754A1/en active Pending
- 2021-01-22 US US17/791,395 patent/US20230242602A1/en active Pending
- 2021-01-22 JP JP2022544353A patent/JP2023511908A/ja active Pending
- 2021-01-22 MX MX2022008953A patent/MX2022008953A/es unknown
- 2021-01-22 CA CA3168805A patent/CA3168805A1/en active Pending
- 2021-01-22 AR ARP210100163A patent/AR121118A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023511908A (ja) | 2023-03-23 |
| CN115210251A (zh) | 2022-10-18 |
| BR112022014160A2 (pt) | 2022-09-13 |
| AU2021209699A1 (en) | 2022-07-21 |
| US20230242602A1 (en) | 2023-08-03 |
| MX2022008953A (es) | 2022-08-15 |
| UY39036A (es) | 2021-08-31 |
| WO2021151012A1 (en) | 2021-07-29 |
| KR20220131273A (ko) | 2022-09-27 |
| TW202134288A (zh) | 2021-09-16 |
| EP4093754A1 (en) | 2022-11-30 |
| CA3168805A1 (en) | 2021-07-29 |
| IL294535A (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121118A1 (es) | Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| CR8978A (es) | Proteinas de fusion de dominio de union | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| MX2024012898A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas | |
| MX2020001855A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides. | |
| CL2023000853A1 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| BR112018067946A2 (pt) | formulações tópicas contendo ciclosporina e usos das mesmas | |
| BR112018006873A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| CL2021002483A1 (es) | Compuestos y composiciones como moduladores de la señalización tlr | |
| EA202092305A1 (ru) | Соединения в качестве модуляторов сигнализации tlr2 | |
| EP3416500A4 (en) | COMBINATION OF MEDICINAL PRODUCTS AND METHODS FOR THE STIMULATION OF THE EMBRYONAL REGENERATION FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | |
| MX2024005777A (es) | Isoxazolidinas como inhibidores de ripk1 y uso de estas. | |
| AU2012280776B2 (en) | Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases | |
| UY39450A (es) | Nuevos factores de transcripción de la proteína de dedo de zinc para reprimir la expresión de alfa- sinucleina | |
| BR112019023817A8 (pt) | Composições tópicas e métodos para o tratamento de doenças da pele | |
| BR112022004475A2 (pt) | Proteínas de fusão nkg2d e usos das mesmas | |
| BR112021022742A2 (pt) | Método de expressão de proteínas de ligação de antígeno no sistema nervoso e uso de um construto de expressão | |
| AR120151A1 (es) | FACTORES DE TRANSCRIPCIÓN DE PROTEÍNAS DE DEDOS DE ZINC PARA LA REPRESIÓN DE LA EXPRESIÓN DE a-SINUCLEÍNA | |
| MX2020010301A (es) | Fragmentos de cdnf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. | |
| PE20240648A1 (es) | Metodos para reducir la expresion de tau | |
| Lai | Seminar | |
| Jarrett et al. | 80. Minocycline attenuates stress-induced changes in leukocyte activation and anxiety-like behavior |